A Standardised, Generic, Validated Approach to Stratify the Magnitude of Clinical Benefit That can be Anticipated From Anti-cancer Therapies

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

N. I. Cherny; R. Sullivan; U. Dafni; J. M. Kerst; A. Sobrero; C. Zielinski; E. G. E. de Vries; M. J. Piccart


Ann Oncol. 2015;26(8):1547-1573. 

In This Article


ESMO is committed to promoting rational, responsible and affordable cancer care, the importance of organisational integrity, and the promotion of best use of limited health care resources. The ESMO-MCBS v1.0 was born out of these considerations. It represents a first version of a well-validated tool to stratify the magnitude of clinical benefit for new anti-cancer treatments and is applicable over a full range of solid tumours. Based on the data derived from well-structured phase III clinical trials or meta-analyses, the tool uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of benefit that can be anticipated from any new treatment. The ESMO-MCBS is an important first step to the major ongoing task of evaluating value in cancer care which is essential for appropriate uses of limited public and personal resources for affordable cancer care. The ESMO-MCBS will be a dynamic tool and its criteria will be revised on a regular basis pending peer reviewed feedback and developments in cancer research and therapies.